Qiagen N.V. $QGEN Stock Position Raised by Engineers Gate Manager LP

Key Points

• Engineers Gate Manager LP more than doubled its Qiagen position in the second quarter, increasing holdings by 107.7% to 74,567 shares valued at approximately $2.9 million.
• Qiagen reported quarterly adjusted earnings of $0.62 per share and revenue of $535.04 million, both exceeding analyst expectations. Revenue rose 0.2% year over year, and the company maintained full-year earnings guidance of $2.43 per share.
• Qiagen shares opened at $42.39, while analysts maintained a consensus “Hold” rating with an average price target of $43.51; institutional investors own 70% of the stock.

Engineers Gate Manager LP grew its position in shares of Qiagen N.V. (NYSE:QGEN - Free Report) by 107.7% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 74,567 shares of the company's stock after buying an additional 38,658 shares during the quarter. Engineers Gate Manager LP's holdings in Qiagen were worth $2,916,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also made changes to their positions in the company. Price T Rowe Associates Inc. MD increased its holdings in Qiagen by 12.1% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 8,429,424 shares of the company's stock worth $379,072,000 after buying an additional 906,589 shares during the last quarter. Deutsche Bank AG lifted its stake in Qiagen by 9.7% in the fourth quarter. Deutsche Bank AG now owns 7,907,801 shares of the company's stock valued at $355,614,000 after acquiring an additional 697,342 shares during the last quarter. Amundi lifted its stake in Qiagen by 12.4% in the first quarter. Amundi now owns 4,757,681 shares of the company's stock valued at $190,498,000 after acquiring an additional 524,959 shares during the last quarter. Boston Partners bought a new stake in Qiagen in the third quarter worth approximately $179,450,000. Finally, Norges Bank bought a new stake in Qiagen in the fourth quarter worth approximately $166,500,000. Institutional investors own 70.00% of the company's stock.

Qiagen Trading Down 0.3%

Shares of QGEN stock opened at $42.39 on Monday. Qiagen N.V. has a 12 month low of $32.53 and a 12 month high of $57.81. The company has a market cap of $8.74 billion, a PE ratio of 21.72, a price-to-earnings-growth ratio of 4.23 and a beta of 0.63. The company has a quick ratio of 2.31, a current ratio of 2.85 and a debt-to-equity ratio of 0.48. The business's 50 day moving average is $42.20 and its two-hundred day moving average is $40.13.

Qiagen (NYSE:QGEN - Get Free Report) last issued its quarterly earnings data on Wednesday, August 5th. The company reported $0.62 earnings per share for the quarter, topping analysts' consensus estimates of $0.60 by $0.02. Qiagen had a net margin of 19.49% and a return on equity of 14.47%. The business had revenue of $535.04 million during the quarter, compared to analysts' expectations of $527.50 million. During the same period in the previous year, the company earned $0.60 earnings per share. Qiagen's revenue for the quarter was up .2% on a year-over-year basis. Qiagen has set its FY 2026 guidance at 2.430- EPS. Equities analysts predict that Qiagen N.V. will post 2.43 EPS for the current year.

Analysts Set New Price Targets

A number of research analysts have recently weighed in on QGEN shares. Barclays set a $40.00 price target on shares of Qiagen and gave the company an "equal weight" rating in a report on Friday, August 7th. Jefferies Financial Group reiterated a "buy" rating and issued a $48.00 price objective on shares of Qiagen in a report on Thursday, August 6th. Morgan Stanley reissued an "overweight" rating on shares of Qiagen in a research report on Friday. UBS Group assumed coverage on Qiagen in a report on Wednesday. They set a "neutral" rating and a $47.00 target price on the stock. Finally, JPMorgan Chase & Co. raised their target price on Qiagen from $45.00 to $50.00 and gave the company an "overweight" rating in a report on Friday, August 7th. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and nine have given a Hold rating to the company. Based on data from MarketBeat.com, Qiagen currently has a consensus rating of "Hold" and a consensus target price of $43.51.

Qiagen Profile

QIAGEN N.V. is a global provider of sample preparation, molecular testing and bioinformatics solutions used in life sciences research, molecular diagnostics and applied testing. The company develops technologies that help customers isolate and analyze DNA, RNA and other biological materials from blood, tissue and other samples.

Its offerings include laboratory instruments, consumables, assay kits and software. Key product areas include automated sample-processing systems, polymerase chain reaction (PCR) and digital PCR solutions, next-generation sequencing workflows, bioinformatics tools, and diagnostic tests such as QuantiFERON for tuberculosis testing and QIAstat-Dx for syndromic testing.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.